Strategic Acquisition Cytobank was acquired by Beckman Coulter in 2019, integrating its single-cell analysis platform into a broader portfolio of laboratory instrumentation and diagnostics, presenting cross-selling opportunities for advanced cytometry solutions.

Innovative Platform The company maintains an up-to-date informatics platform with recent updates like Cytobank 7.2 and new analytics features such as FlowSOM, indicating a focus on cutting-edge software solutions that can be bundled with hardware for comprehensive cell analysis workflows.

Focused Growth Funding Receiving a $1.3 million SBIR Phase II grant from the NIH to enhance machine learning capabilities underscores potential for scalable, AI-driven single-cell analysis tools that could appeal to research labs and biotech firms seeking innovative data solutions.

Limited Revenue, Niche Market With revenue under one million dollars and a small team, Cytobank is a specialized player in the biotech research industry, offering targeted software solutions that might benefit from strategic partnerships with larger institutions or equipment vendors.

Technology Stack & Data Utilizing cloud and web technologies such as Amazon S3, Google Analytics, and Cloudflare CDN, Cytobank is positioned to deliver scalable, reliable analytics services suitable for institutions seeking advanced, cloud-based cytometry analysis platforms.